-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, data from a study published in the journal PLOS Medicine in the United States showed that Johnson & Johnson (JNJ)'s Ebola vaccine program (2-dose immunization)-Zabdeno® (Ad26.
Johnson & Johnson's Ebola vaccine program (Zabdeno®+Mvabea®) received marketing authorization from the European Commission (EC) in July 2020, and was prequalified by the World Health Organization (WHO) in April 2021
Since the outbreak of the West Africa epidemic in 2014, with the power of global public-private cooperation, Johnson & Johnson's Ebola vaccine program (Zabdeno®+Mvabea®) obtained regulatory approval in less than 6 years
The data published in the journal PLOS Medicine come from the second phase of the EBL2002 study
Since the Ebola virus was discovered in 1976, more than 30 outbreaks have been announced, the most serious of which has occurred in Africa in the past seven years
Johnson & Johnson responded to the recent Ebola epidemic by providing vaccine programs to governments and the World Health Organization (WHO)
Note: The original text has been deleted
Original source: Statement on Data Published in PLOS Medicine on Tolerability and Immune Response of Johnson & Johnson Ebola Vaccine Regimen in Adults Living with HIV